Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease With 3 Years of Treatment: Results From the FORTIFY Open-Label Long-Term Extension

被引：0
|
作者：
Ferrante, M. [1 ]
Panaccione, R. [2 ]
Colombel, J. F. [3 ]
Dubinsky, M. C. [4 ]
Hisamatsu, T. [5 ]
Lindsay, J. O. [6 ]
Song, A. [7 ]
Yao, Y. [8 ]
Zhang, Y. [8 ]
Zambrano, J. [9 ]
Aponte, F. [10 ]
Duan, W. R. [11 ]
D'Haens, G. [12 ]
机构：
[1] Katholieke Univ Leuven, Dept Gastroenterol & Hepatol, Univ Hosp Leuven, Leuven, Belgium
[2] Univ Calgary, Div Gastroenterol & Hepatol, Inflammatory Bowel Dis Unit, Calgary, AB, Canada
[3] Icahn Sch Med Mt Sinai, Dept Med, Henry D Janowitz Div Gastroenterol, New York, NY USA
[4] Icahn Sch Med Mt Sinai, Susan & Leonard Feinstein IBD Ctr, New York, NY USA
[5] Kyorin Univ, Sch Med, Dept Gastroenterol & Hepatol, Tokyo, Japan
[6] Queen Mary Univ London, Ctr Immunobiol Barts, London Sch Med & Dent, London, England
[7] AbbVie, Clin Dev, N Chicago, IL USA
[8] AbbVie, Stat, N Chicago, IL USA
[9] AbbVie, US Med Affairs, N Chicago, IL USA
[10] AbbVie, Int Med Affairs, N Chicago, IL USA
[11] AbbVie, Med Safety Evaluat, N Chicago, IL USA
[12] Univ Amsterdam, Dept Gastroenterol & Hepatol, Amsterdam UMC, Amsterdam, Netherlands
来源：
JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷
关键词：
D O I：
10.1093/ecco-jcc/jjae190.0055
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP016
引用
收藏
页码：i109 / i111
页数：3
相关论文
共 50 条
  • [31] Long-term safety and efficacy of ABT-874 for the treatment of moderate to severe psoriasis: Interim analysis from an open-label extension study
    Langley, Richard
    Valdes, Joaquin
    Gordon, Kenneth
    Papp, Kim
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB148 - AB148
  • [32] Long-Term Safety and Efficacy of Open-Label Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
    Deleuran, Mette
    Thaci, Diamant
    Beck, Lisa A.
    Forman, Seth
    Soong, Weily
    Hussain, Iftikhar
    Bissonnette, Robert
    Bouaziz, Jean-David
    Gelfand, Joel
    Sher, Lawrence
    Chen, Zhen
    Akinlade, Bolanle
    Gadkari, Abhijit
    Eckert, Laurent
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Ardeleanu, Marius
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 139 (02) : AB381 - AB381
  • [33] Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study
    Deleuran, Mette
    Thaci, Diamant
    Beck, Lisa A.
    de Bruin-Weller, Marjolein
    Blauvelt, Andrew
    Forman, Seth
    Bissonnette, Robert
    Reich, Kristian
    Soong, Weily
    Hussain, Iftikhar
    Foley, Peter
    Hide, Michihiro
    Bouaziz, Jean-David
    Gelfand, Joel M.
    Sher, Lawrence
    Schuttelaar, Marie L. A.
    Wang, Chen
    Chen, Zhen
    Akinlade, Bolanle
    Gadkari, Abhijit
    Eckert, Laurent
    Davis, John D.
    Rajadhyaksha, Manoj
    Staudinger, Heribert
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Ardeleanu, Marius
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (02) : 377 - 388
  • [34] Long-term safety and efficacy of open-label dupilumab in patients with moderate-to-severe atopic dermatitis
    Deleuran, M.
    Thaci, D.
    Beck, L.
    Forman, S.
    Soong, W.
    Hussain, I.
    Bissonnette, R.
    Bouaziz, J.
    Gelfand, J.
    Lawrence, S.
    Chen, Z.
    Akinlade, B.
    Gadkari, A.
    Eckert, L.
    Graham, N.
    Ardeleanu, M.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 34 - 34
  • [35] Safety and efficacy of bimekizumab through 2 years in patients with moderate to severe plaque psoriasis: Long-term results from BE SURE randomised controlled trial and BE BRIGHT open-label extension
    Thaci, Diamant
    Vender, Ronald
    de Rie, Menno
    Conrad, Curdin
    Pariser, David
    Strober, Bruce
    Vanvoorden, Veerle
    Peterson, Luke
    Madden, Cynthia
    De Cuyper, Dirk
    Rubel, Diana
    Kimball, Alexa
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 14 - 15
  • [36] Efficacy and safety of briakinumab for treatment of moderate to severe psoriasis in patients previously receiving etanercept: Results from an open-label extension
    Strober, Bruce
    Leonardi, Craig
    Williams, David A.
    Olds, Michele
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB191 - AB191
  • [37] Long-Term Safety and Efficacy of Voxelotor for Patients with Sickle Cell Disease: Results from an Open-Label Extension of the Phase 3 HOPE Trial
    Achebe, Maureen
    Hassab, Hoda
    Alkindi, Salam
    Brown, R. Clark Clark
    Telfer, Paul
    Biemond, Bart J.
    Gordeuk, Victor R.
    Lipato, Thokozeni
    Tonda, Margaret
    Gray, Sarah
    Howard, Joanna
    BLOOD, 2021, 138
  • [38] Long-term safety and efficacy of zafirlukast in the treatment of asthma: interim results of an open-label extension trial
    Grossman, J
    Smith, LJ
    Wilson, AM
    Thyrum, PT
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1999, 82 (04) : 361 - 369
  • [39] Long-Term Safety and Efficacy of Donepezil in Patients with Severe Alzheimer's Disease: Results from a 52-Week, Open-Label, Multicenter, Extension Study in Japan
    Homma, Akira
    Imai, Yukimichi
    Tago, Hisao
    Asada, Takashi
    Shigeta, Masahiro
    Iwamoto, Toshihiko
    Takita, Masashi
    Arimoto, Itaru
    Koma, Hiroshi
    Takase, Takao
    Ohbayashi, Toshio
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2009, 27 (03) : 232 - 239
  • [40] Long-term safety and tolerability of memantine: an open-label extension study in patients with mild to moderate Alzheimer's disease
    Bakchine, S.
    Rainer, M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 : S529 - S529
12345